| scholarly article | Q13442814 |
| P2093 | author name string | Nolan GP | |
| Nishimura MI | |||
| Orentas RJ | |||
| Roskopf SJ | |||
| P433 | issue | 2 | |
| P921 | main subject | Epstein–Barr virus | Q6900 |
| P304 | page(s) | 220-228 | |
| P577 | publication date | 2001-02-01 | |
| P1433 | published in | Clinical Immunology | Q15752921 |
| P1476 | title | Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide | |
| P478 | volume | 98 |
| Q47549907 | A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy |
| Q38417056 | Adoptive T-cell therapy in the treatment of viral and opportunistic fungal infections |
| Q37980749 | Adoptive immunotherapy of cancer: Gene transfer of T cell specificity |
| Q34726045 | Adoptive transfer of T-cell immunity |
| Q44935678 | Alteration of the gene expression profile of T-cell receptor αβ-modified T-cells with diffuse large B-cell lymphoma specificity |
| Q36675921 | An Influenza Virus M2 Protein Specific Chimeric Antigen Receptor Modulates Influenza A/WSN/33 H1N1 Infection In Vivo |
| Q42136462 | CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting. |
| Q40777946 | Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer |
| Q33766995 | Engineering cord blood to improve engraftment after cord blood transplant |
| Q36328391 | Enhancing siRNA effects in T cells for adoptive immunotherapy |
| Q35238310 | Evaluation of Epstein-Barr virus latent membrane protein 2 specific T-cell receptors driven by T-cell specific promoters using lentiviral vector |
| Q45158993 | Fulminant experimental autoimmune encephalo-myelitis induced by retrovirally mediated TCR gene transfer |
| Q33185580 | Genetic engineering of T cell specificity for immunotherapy of cancer |
| Q35826514 | Genetic modification of T lymphocytes for adoptive immunotherapy |
| Q39382670 | Immunotherapy for transplantation-associated viral infections |
| Q37268305 | Immunotherapy targeting EBV-expressing lymphoproliferative diseases |
| Q36407236 | Improving T cell therapy for cancer |
| Q35008880 | Nasopharyngeal carcinoma and the EBV-specific T cell response: prospects for immunotherapy |
| Q35190684 | Posttransplant lymphoproliferative disease: pathogenesis, monitoring, and therapy |
| Q35126976 | Redirecting T lymphocyte specificity using T cell receptor genes |
| Q40572007 | Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer |
| Q42364280 | Retroviral transfer of T-cell receptor genes produces cells with a broad range of lytic activity |
| Q35909334 | Somatic cell engineering and the immunotherapy of leukemias and lymphomas |
| Q33655849 | Strategies to genetically engineer T cells for cancer immunotherapy |
| Q24815775 | T cell avidity and tumor recognition: implications and therapeutic strategies |
| Q37058107 | T cells for viral infections after allogeneic hematopoietic stem cell transplant |
| Q36842738 | T-cell receptor gene transfer by lentiviral vectors in adoptive cell therapy |
| Q34718133 | T-cell-receptor gene therapy |
| Q30831500 | TCR reconstitution in Jurkat reporter cells facilitates the identification of novel tumor antigens by cDNA expression cloning |
| Q92091538 | Targeting cancers through TCR-peptide/MHC interactions |
| Q35037678 | Targeting tumours with genetically enhanced T lymphocytes |
| Q33649735 | Transduction of human T cells with a novel T-cell receptor confers anti-HCV reactivity. |
| Q40328361 | Transduction of primary lymphocytes with Epstein-Barr virus (EBV) latent membrane protein-specific T-cell receptor induces lysis of virus-infected cells: A novel strategy for the treatment of Hodgkin's disease and nasopharyngeal carcinoma |
| Q40553796 | Transgenic TCR expression: comparison of single chain with full-length receptor constructs for T-cell function. |
| Q37419728 | Treatment of lymphoma with adoptively transferred T cells. |
Search more.